See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Phase 3 Study Results of Obicetrapib on Alzheimer Disease Biomarker Progression: Philip Scheltens, MD, PhD

Summary by neurologylive.com
The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

neurologylive.comneurologylive.com

Phase 3 Study Results of Obicetrapib on Alzheimer Disease Biomarker Progression: Philip Scheltens, MD, PhD

The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Sunday, August 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Maryland icon

Maryland

News
For You
SearchBlindspotLocal